SHEP-001

SHEP-001 is a small molecule therapeutic being developed by Shepherd Therapeutics for the treatment of various rare cancers. It was identified using the company's proprietary DELVE precision-oncology platform, which integrates machine learning and transcriptomics to map complex biological mechanisms and identify potential drug responses in rare malignancies. SHEP-001 is currently in the IND-enabling and preclinical stages of development for several rare indications, including adenoid cystic carcinoma, adrenocortical carcinoma, carcinoid tumors, cholangiocarcinoma, esophageal cancer, and Ewing's sarcoma. While the drug is part of a pipeline of assets (SHEP-001 to SHEP-006) targeting rare diseases, its specific molecular target and mechanism of action have not been publicly disclosed.